IN THE SPECIFICATION

Please replace the paragraph on page 4, lines 8-26 in the specification with the following paragraph:

--In a preferred embodiment (see PDX-1 in Table 1), the medium comprises tryptone, in a concentration ranging from about 15 to about 25 g/L, with a preferred concentration of about 16 to about 18 g/L, with a further preferred concentration of about 17 g/L; peptone, in a concentration ranging from about 1 to about 5 g/L, with a preferred concentration of about 2 to about 4 g/L, with a further preferred concentration of about 3 g/L; sodium chloride, in a concentration ranging from about 1 to about 10 g/L, with a preferred concentration of about 2.5 to about 7.5 g/L, with a further preferred concentration of about 5 g/L; anhydrous dibasic potassium phosphate, in a concentration ranging from about 1 to about 10 g/L, with a preferred concentration of about 2.5 to about 7.5 g/L, with a further preferred concentration of about 5 g/L; yeast extract, in a concentration ranging from about 1 to about 10 g/L, with a preferred concentration of about 2.5 to about 7.5 g/L, with a further preferred concentration of about 6 g/L; **cycloheximide** ~~**cyclohexamide**~~, in a concentration ranging from about 0.01 to 0.1 g/L, with a preferred concentration of about 0.025 to about 0.075 g/L, with a further preferred concentration of about 0.05 g/L; acriflavin, in a concentration ranging from no more than about 0.01; naladixic acid, in a concentration ranging from about 0.01 to about 0.1 g/L, with a preferred concentration of about 0.025 to about 0.075 g/L, with a further preferred concentration of about 0.04 g/L; and esculin, in a concentration ranging from about 0.5 to 5 g/L, with a preferred concentration of about 0.75 to about 2 g/L, with a further preferred concentration of about 1 g/L.—

Please replace the paragraph on page 4, lines 27-31 in the specification with the following paragraph:

-- In an especially preferred embodiment (see PDX-2 in Table 1), the selective medium of the present invention comprises tryptone, peptone, sodium chloride, anhydrous dibasic potassium

phosphate, yeast extract, **cycloheximide** ~~**cyclohexamide**~~, naladixic acid and esculin in the amounts described above but contains no acriflavin. Acriflavin consistently inhibits all of the *Bacillus spp.* but also inhibits the hemolytic activity of *L. monocytogenes*.--

Please replace the paragraph on page 5, lines 15-19 of the specification with the following paragraph:

--The ingredients of the selective medium of the present invention are dissolved in distilled water and autoclaved at approximately 121 psig until sterile, usually about 15 min. After cooling, supplements are added. Preferred supplements include **ceftazidime** ~~**ceftazimide**~~, **phosphomycin** ~~**phosphomyocin**~~, polymyxin E, ferric ammonium citrate, lithium chloride and nitrofurantoin (Table 2).--

Please replace the paragraph on page 5, lines 20-24 of the specification with the following paragraph:

--**Ceftazidime** ~~**Ceftazimide**~~, **phosphomycin** ~~**phosphomyocin**~~, polymyxin E and nitrofurantoin are all antibiotics. **Ceftazidime** ~~**Ceftazimide**~~ is a third generation cephalosporin, and acts to inhibit cell wall synthesis. Other cephalosporins such as ceftriaxone, moxolactam, cefotaxime, cefpodoxime, ceftizoxime, cefoperazone may also be used. The medium of the present invention preferably contains **ceftazidime** ~~**ceftazimide**~~ in a concentration ranging from about 0.04 g/L.--

Please replace Table 1 on page 6 with the following table:

--TABLE 1: Medium Formulation, Versions PDX-1 and PDX-2.

| Ingredient | PDX-1 (g/L) | PDX-2 (g/L) |
|---|---|---|
| Tryptone | 17.0 | 17.0 |
| Peptone | 3.0 | 3.0 |
| Sodium Chloride | 5.0 | 5.0 |
| Dibasic Potassium Phosphate (anhydrous) | 6.0 | 6.0 |
| Yeast extract | 6.0 | 6.0 |
| **Cycloheximide** ~~**Cyclohexamide**~~ | 0.05 | 0.05 |
| Acriflavin | 0.01 | - |
| Naladixic acid | 0.04 | 0.04 |
| Esculin | 1.0 | 1.0 |

--

Please replace Table 2 starting on page 7, line 15 and ending on page 8, line 6 with the following table:

--TABLE 2: Supplements.

| Supplement name | PDX-1 | PDX-2 |
|---|---|---|
| **Ceftazidime** ~~**Ceftazimide**~~ | 0.04 g/L | 0.04 g/L |
| Phosphomycin | 0.04 g/L | 0.04 g/L |
| Polymyxin E | 0.01 g/L | 0.01 g/L |
| Ferric Ammonium Citrate | 0.5 g/L | 0.5 g/L |
| Lithium Chloride* | 5.0 g/L | 5.0 g/L |
| Nitrofurantoin** | - | 0.006 g/L |

*Lithium chloride is exothermic when dissolved in water. Appropriate care must be taken when adding it to the medium.

**Nitrofurantoin is insoluble in water. A 10 mg/mL stock solution was made in sterile DMSO. The nitrofurantoin/DMSO stock solution was then added to the rest of the medium (600 microliters of stock solution/L medium yields 0.006 g/L nitrofurantoin in the final medium). Solid-medium plates were made from the liquid

medium by adding 15 g agar per liter of liquid medium, bringing the medium to a boil to dissolve the agar, cooling the solutions, and sterilizing the same.--